Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ABDUL RAFEH NAQASH

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1528499712
CMS profile
4217943
Location
OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$7,378.87

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Foundation Medicine, Inc. $7,352.50 1
RECORDATI_RARE_DISEASES_INC. $26.37 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ABDUL RAFEH NAQASH

NPI 1528499712 · CMS profile ID 4217943

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1528499712?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ABDUL RAFEH NAQASH, NPI 1528499712, CMS profile ID 4217943. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528499712?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ABDUL RAFEH NAQASH, NPI 1528499712, CMS profile ID 4217943. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528499712?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ABDUL RAFEH NAQASH, NPI 1528499712, CMS profile ID 4217943, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1528499712?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $7,378.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Foundation Medicine, Inc. $7,352.5009/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058782441 CMS
RECORDATI_RARE_DISEASES_INC. $26.3709/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060353881 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $222.96 15
PY2020 $13.46 1
PY2023 $7,378.87 2
PY2024 $11,838.80 9
PY2025 $3,667.10 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $443.22 1
PY2025 Principal investigator $340,851.02 231
PY2024 Principal investigator $416,792.13 124
PY2023 Principal investigator $259,878.25 67
PY2022 Principal investigator $92,521.38 35

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2024 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS- SARASOTA CATTLEMEN
M23-385 ABBV-706 Ph 1 2L-4L SCLC No dispute reported 06/30/2026 1100764509
Principal investigator 1 EMD Serono Research & Development Institute, Inc. $5,033.61 12/16/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIV OF OKL
Phase 1b Study of Avelumab in Combination with Axl Inhibitor AVB-S6-500 in Patients with Advanced Urothelial Carcinoma No dispute reported 06/30/2026 1124710473
Principal investigator 1 Coherus Biosciences Inc. $300.00 11/27/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272565
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 11/27/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272567
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 11/27/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272657
Principal investigator 1 Merck Sharp & Dohme LLC $49,680.00 11/26/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors No dispute reported 06/30/2026 1136397125
Principal investigator 1 ADC Therapeutics America, Inc. $2,300.63 11/15/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521560
Principal investigator 1 ADC Therapeutics America, Inc. $1,873.13 11/15/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521562
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 11/15/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521564
Principal investigator 1 ADC Therapeutics America, Inc. $478.13 11/15/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521566
Principal investigator 1 ADC Therapeutics America, Inc. $2,047.50 11/15/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,703.23 10/28/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082441642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 10/28/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082441646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 10/28/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082441648
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521520
Principal investigator 1 ADC Therapeutics America, Inc. $135.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521522
Principal investigator 1 ADC Therapeutics America, Inc. $1,000.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521524
Principal investigator 1 ADC Therapeutics America, Inc. $445.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521526
Principal investigator 1 ADC Therapeutics America, Inc. $96.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521528
Principal investigator 1 ADC Therapeutics America, Inc. $450.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521530
Principal investigator 1 ADC Therapeutics America, Inc. $75.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521532
Principal investigator 1 ADC Therapeutics America, Inc. $455.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521534
Principal investigator 1 ADC Therapeutics America, Inc. $156.25 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521536
Principal investigator 1 ADC Therapeutics America, Inc. $120.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521538
Principal investigator 1 ADC Therapeutics America, Inc. $500.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521540
Principal investigator 1 ADC Therapeutics America, Inc. $2,388.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521542
Principal investigator 1 ADC Therapeutics America, Inc. $375.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521544
Principal investigator 1 ADC Therapeutics America, Inc. $88.75 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521546
Principal investigator 1 ADC Therapeutics America, Inc. $159.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521548
Principal investigator 1 ADC Therapeutics America, Inc. $93.75 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521550
Principal investigator 1 ADC Therapeutics America, Inc. $94.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521552
Principal investigator 1 ADC Therapeutics America, Inc. $4,087.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521554
Principal investigator 1 ADC Therapeutics America, Inc. $270.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521556
Principal investigator 1 ADC Therapeutics America, Inc. $1,972.00 10/18/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521558
Principal investigator 1 PFIZER INC. $2,000.00 10/09/2024 Non-covered Recipient Entity
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130959997
Principal investigator 1 PFIZER INC. $14,000.00 10/09/2024 Non-covered Recipient Entity
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130960002
Principal investigator 1 Coherus Biosciences Inc. $75.00 09/19/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272587
Principal investigator 1 Coherus Biosciences Inc. $1,228.00 09/19/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272589
Principal investigator 1 ADC Therapeutics America, Inc. $94.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521496
Principal investigator 1 ADC Therapeutics America, Inc. $445.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521500
Principal investigator 1 ADC Therapeutics America, Inc. $159.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521502
Principal investigator 1 ADC Therapeutics America, Inc. $199.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521504
Principal investigator 1 ADC Therapeutics America, Inc. $455.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521506
Principal investigator 1 ADC Therapeutics America, Inc. $75.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521508
Principal investigator 1 ADC Therapeutics America, Inc. $93.75 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521510
Principal investigator 1 ADC Therapeutics America, Inc. $96.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521512
Principal investigator 1 ADC Therapeutics America, Inc. $500.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521514
Principal investigator 1 ADC Therapeutics America, Inc. $135.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521516
Principal investigator 1 ADC Therapeutics America, Inc. $450.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521518
Principal investigator 1 Coherus Biosciences Inc. $1,040.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272591
Principal investigator 1 Coherus Biosciences Inc. $37.50 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272593
Principal investigator 1 Coherus Biosciences Inc. $375.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272595
Principal investigator 1 Coherus Biosciences Inc. $65.25 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272597
Principal investigator 1 Coherus Biosciences Inc. $32.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272599
Principal investigator 1 Coherus Biosciences Inc. $119.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272601
Principal investigator 1 Coherus Biosciences Inc. $1,228.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272603
Principal investigator 1 Coherus Biosciences Inc. $425.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272605
Principal investigator 1 Coherus Biosciences Inc. $1,120.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272607
Principal investigator 1 Coherus Biosciences Inc. $156.25 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272609
Principal investigator 1 Coherus Biosciences Inc. $390.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272611
Principal investigator 1 Coherus Biosciences Inc. $125.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272613
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272615
Principal investigator 1 Coherus Biosciences Inc. $300.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272617
Principal investigator 1 Coherus Biosciences Inc. $98.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272619
Principal investigator 1 Coherus Biosciences Inc. $2,388.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272621
Principal investigator 1 Coherus Biosciences Inc. $43.75 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272623
Principal investigator 1 Coherus Biosciences Inc. $4,000.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272625
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272629
Principal investigator 1 Coherus Biosciences Inc. $375.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272631
Principal investigator 1 Coherus Biosciences Inc. $4,000.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272633
Principal investigator 1 Coherus Biosciences Inc. $98.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272635
Principal investigator 1 Coherus Biosciences Inc. $119.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272637
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272639
Principal investigator 1 Coherus Biosciences Inc. $156.25 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272641
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272643
Principal investigator 1 Coherus Biosciences Inc. $37.50 09/06/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272645
Principal investigator 1 PFIZER INC. $4,338.00 08/28/2024 Non-covered Recipient Entity
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130959990
Principal investigator 1 PFIZER INC. $250.00 08/07/2024 Non-covered Recipient Entity
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130960056
Principal investigator 1 ABBVIE INC. $2,869.00 07/15/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100729666
Principal investigator 1 ABBVIE INC. $1,586.00 07/15/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100729668
Principal investigator 1 ABBVIE INC. $3,458.00 07/15/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100729670
Principal investigator 1 ABBVIE INC. $1,586.00 07/15/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100729672
Principal investigator 1 ABBVIE INC. $3,575.00 07/15/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100729674
Principal investigator 1 ABBVIE INC. $858.00 07/15/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100729702
Principal investigator 1 ABBVIE INC. $858.00 07/15/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100729704
Principal investigator 1 Exelixis Inc. $80.00 07/15/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138631902
Principal investigator 1 ADC Therapeutics America, Inc. $43.75 07/12/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1126521498
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,172.55 07/03/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $579.15 07/03/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,065.50 07/03/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,549.55 07/03/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,461.40 07/03/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $278.10 07/03/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,039.60 07/03/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $118.80 07/03/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $438.75 07/03/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,093.50 07/03/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430742
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 06/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1126521464
Principal investigator 1 Coherus Biosciences Inc. $369.50 06/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272575
Principal investigator 1 Coherus Biosciences Inc. $425.00 06/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272577
Principal investigator 1 Coherus Biosciences Inc. $125.00 06/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272579
Principal investigator 1 Coherus Biosciences Inc. $4,000.00 06/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272581
Principal investigator 1 Coherus Biosciences Inc. $1,228.00 06/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272583
Principal investigator 1 Coherus Biosciences Inc. $65.25 06/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272585
Principal investigator 1 Coherus Biosciences Inc. $125.00 06/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272627
Principal investigator 1 Coherus Biosciences Inc. $4,000.00 06/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272647
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 05/24/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272573
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 05/17/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272569
Principal investigator 1 Coherus Biosciences Inc. $1,220.00 05/17/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272571
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 05/17/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272649
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 05/17/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272651
Principal investigator 1 Coherus Biosciences Inc. $1,850.00 05/17/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272655
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 05/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1126521466
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 05/03/2024 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1126521468
Principal investigator 1 Merck Sharp & Dohme LLC $21,300.00 04/25/2024 Non-covered Recipient Entity
University Of Oklahoma OU Health Stephenson Cancer Center
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1136444973
Principal investigator 1 Exelixis Inc. $360.00 04/10/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138631900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 03/25/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082422153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 03/25/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082422155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 03/25/2024 Non-covered Recipient Entity
BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082422157
Principal investigator 1 Exelixis Inc. $1,650.00 02/09/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138631208
Principal investigator 1 Exelixis Inc. $1,650.00 01/24/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138631202
Principal investigator 1 Exelixis Inc. $285.00 01/24/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138631204
Principal investigator 1 Exelixis Inc. $1,650.00 01/24/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138631206
Principal investigator 1 Eli Lilly and Company $170,431.50 01/15/2024 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS No dispute reported 06/30/2026 1137367111